Sally Dewhurst

Director/Board Member at

Grey Wolf Therapeutics Ltd.

Health Technology

Consumer Services

Finance

Profile

Sally Dewhurst is currently a Director at Grey Wolf Therapeutics Ltd., a Principal at Oxford Science Enterprises PLC, and a Board Member at Alethiomics Ltd. Previously, she was a Board Observer at DJS Antibodies Ltd. Ms. Dewhurst graduated from the University of Durham in 2011.

Sally Dewhurst active positions

Companies	Position	Start
Grey Wolf Therapeutics Ltd. Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs	Director/Board Member	24/01/2023
Oxford Science Enterprises PLC Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million.	Private Equity Investor	01/07/2023
Alethiomics Ltd. Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company	Director/Board Member	01/11/2022

All active positions of Sally Dewhurst

Former positions of Sally Dewhurst

Companies	Position	End
DJS Antibodies Ltd. DJS Antibodies Ltd. BiotechnologyHealth Technology Operates as a biotechnology company	Corporate Officer/Principal	01/10/2022

See the detail of Sally Dewhurst's experience

Training of Sally Dewhurst

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Sally Dewhurst's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
University of Durham University of Durham Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Oxford Science Enterprises PLC Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million.	Finance
DJS Antibodies Ltd. DJS Antibodies Ltd. BiotechnologyHealth Technology Operates as a biotechnology company	Health Technology
Grey Wolf Therapeutics Ltd. Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs	Health Technology
Alethiomics Ltd. Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company	Commercial Services